These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 18768226)

  • 1. Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: a 21-month follow-up "real world" study.
    Calabria M; Geroldi C; Lussignoli G; Sabbatini F; Zanetti O
    Arch Gerontol Geriatr; 2009; 49(1):e6-11. PubMed ID: 18768226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
    Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
    Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A qualitative analysis of the mini mental state examination on Alzheimer's disease patients treated with cholinesterase inhibitors.
    Lucchi E; Minicuci N; Magnifico F; Mondini S; Calza A; Avanzi S; Villani D; Bellelli G; Trabucchi M
    Arch Gerontol Geriatr Suppl; 2004; (9):253-63. PubMed ID: 15207422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
    Cortes F; Portet F; Touchon J; Vellas B
    J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle.
    Pakrasi S; Mukaetova-Ladinska EB; McKeith IG; O'Brien JT
    Int J Geriatr Psychiatry; 2003 Oct; 18(10):879-86. PubMed ID: 14533120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective pilot study on the development of cognitive, behavioral and functional disorders in a sample of patients with early dementia of Alzheimer type.
    Coin A; Najjar M; Catanzaro S; Orru G; Sampietro S; Sergi G; Manzato E; Perissinotto E; Rinaldi G; Sarti S; Imoscopi A; Ruggiero E; Girardi A
    Arch Gerontol Geriatr; 2009; 49 Suppl 1():35-8. PubMed ID: 19836614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
    Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term cholinergic treatment is not associated with greater risk of weight loss during Alzheimer's disease: data from the French REAL.FR cohort.
    Gillette-Guyonnet S; Cortes F; Cantet C; Vellas B;
    J Nutr Health Aging; 2005; 9(2):69-73. PubMed ID: 15791348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
    Campanozzi MD; Casali E; Neviani F; Martini E; Neri M
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():91-6. PubMed ID: 17317439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease.
    Connelly PJ; Prentice NP; Fowler KG
    Int J Geriatr Psychiatry; 2005 Jul; 20(7):623-8. PubMed ID: 16021654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
    Gauthier S; Juby A; Morelli L; Rehel B; Schecter R;
    Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.
    Wattmo C; Hansson O; Wallin AK; Londos E; Minthon L
    Dement Geriatr Cogn Disord; 2008; 26(3):203-11. PubMed ID: 18769065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
    Small GW; Kaufer D; Mendiondo MS; Quarg P; Spiegel R
    Int J Clin Pract; 2005 Apr; 59(4):473-7. PubMed ID: 15853867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of rapid decline in mini mental state examination in clinical practice for prognosis in Alzheimer's disease.
    Soto ME; Andrieu S; Cantet C; Reynish E; Ousset PJ; Arbus C; Gillette-Guyonnet S; Nourhashémi F; Vellas B;
    Dement Geriatr Cogn Disord; 2008; 26(2):109-16. PubMed ID: 18617740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinesterase inhibitors in Alzheimer's disease: efficacy in a non-selected population.
    Sinforiani E; Banchieri LM; Zucchella C; Bernasconi L; Nappi G
    Funct Neurol; 2003; 18(4):233-7. PubMed ID: 15055749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment.
    Wattmo C; Wallin ÅK; Londos E; Minthon L
    Alzheimer Dis Assoc Disord; 2011; 25(1):63-72. PubMed ID: 20847636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
    Wiig EH; Annas P; Basun H; Andreasen N; Lannfelt L; Zetterberg H; Blennow K; Minthon L
    Acta Neurol Scand; 2010 Mar; 121(3):186-93. PubMed ID: 19785641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.